Skip to main content
Equibles
CBUS logo

CBUS · Cibus, Inc. · Metrics

Track CBUS — free

Use CBUS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CBUS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.42 +0.04 (+2.90%) Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements.”
View the 10-Q filed Aug 13, 2026
Market Cap
$105.47M
Shares
76.43M
Volume · Oct 28 41.31K Avg daily vol (3M) 121.91K

CBUS metrics

81 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.38
Market cap
$105.47M

Price action

20 metrics
Price change (1W)
-0.7%
Price change (30D)
-6.1%
Price change (3M)
-28.9%
Price change (6M)
-2.8%
Price change (YTD)
-20.7%
Price change (1Y)
-16.4%
Trailing year
Price change (5Y)
—
52-week high
$4.05
52-week low
$1.16
Change from 52-week high
-65.9%
Change from 52-week low
+19.0%
Annualized volatility
106.3%
Annualized volatility (3M)
53.3%
Beta
1.9
RSI (14D)
40.8
Price vs SMA 50
-11.0%
Price vs SMA 200
-25.6%
Avg volume (3M)
121,914
Relative volume
0.5
Average dollar volume
$204,386

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
76.43M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
19.8×
reciprocal yield 5.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
24.3×
reciprocal yield 4.1%
P / book
7.1
reciprocal yield 14.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-93.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
-31.4×
EV / revenue historical average (5Y)
-31.4×
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
—
Operating margin
-1,450.6%
Trailing 12 months
Net margin
-2,258.9%
Gross profit (TTM)
$167,000
Operating profit (TTM)
−$63.06M
Net income (TTM)
−$98.19M
Trailing 12 months
Diluted EPS (TTM)
$-1.45
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.07
Gross profit per diluted share (TTM)
$0.17
Operating profit per diluted share (TTM)
$-1.07
EBITDA per diluted share (TTM)
$-0.99
Net income per diluted share (TTM)
$-1.65
Operating cash flow per diluted share (TTM)
$-0.77
Free cash flow per diluted share (TTM)
$-0.98
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$0.62
Stock compensation per diluted share (TTM)
$0.11
Book value per share
$0.93

Growth

11 metrics
Revenue growth YoY
+6.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.35M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+84.4%
Year over year · more shares
Revenue CAGR (3Y)
+185.1%
Revenue CAGR (5Y)
-31.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-663.4%
Return on assets
-31.3%
Debt / equity
0.1
Current ratio
1.6
EBITDA (TTM)
−$57.98M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$19.56M
Latest balance sheet
Cash & equivalents
$20.43M
Total assets
$313.45M
Total debt
$865,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$46.05M
Capital expenditures (TTM)
$267,000
R&D (TTM)
$37.39M
SG&A (TTM)
$20.89M
Stock compensation (TTM)
$6.77M
R&D / revenue
860.2%
Stock compensation / revenue
155.6%

Ownership (13F)

9 metrics
13F filers
63
13F filer change QoQ
-6
Institutional ownership
24.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-19.6%
Holder tenure
9.7
Price vs estimated holder cost
-62.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.7%

Short interest

3 metrics
Short interest
4.1%
Latest settlement · 25.4 days to cover
Days to cover
25.4d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1705843 CUSIP 17166A101 13F (30d) 8 filings 8 filers Visit website Investor relations